Home | News | Innovation

Innovation

CNIO building Innovation
18.07.2019
Potential drugs originated at CNIO to be developed by AUM Biosciences in Asia A group of multi-target anti-tumour compounds, the IBL-300 series, discovered at the Spanish...
Telomeres in mouse embryonic fibroblasts Translational
13.06.2019
EMBO Molecular Medicine. CNIO researchers find effective drug combinations for glioblastoma in mice Usually, scientists study the molecular biology of cancer to find new treatments, but sometimes, it...
Intestinal stem cells with URI, CNIO Basic Research
30.05.2019
Science. CNIO researchers discover a new way to protect against high-dose radiation damage Radiotherapy, a common treatment for cancer, is one of the most effective ways to destroy cancer...
Mouse lymph node Translational
11.04.2019
Journal of Experimental Medicine. CNIO researchers assess melanoma progression with a new liquid biopsy technique When the surgeon surgically removes a melanoma, some patients are said to be ‘cancer-free’ and...
CNIO building Basic Research
09.04.2019
Cancer Cell. CNIO researchers succeed at removing some types of pancreatic cancer in animal models Researchers from the Experimental Oncology Group, led by Mariano Barbacid at the Spanish National...
DLST protein Translational
28.03.2019
The American Journal of Human Genetics. CNIO researchers identify a new gene involved in the development of a rare endocrine tumour Paragangliomas and phaeochromocytomas are very rare neuroendocrine tumours: there are only 3-8 cases...
H12O-CNIO Lung Cancer Clinical Research Unit Translational
03.12.2018
The New England Journal of Medicine (NEJM). An international clinical trial extends the effectiveness of immunotherapy to more lung cancer patients The strategy for triggering the patient’s own immune system to attack cancer, immunotherapy, is...
H12O-CNIO Haematological Malignancies Clinical Research Unit Translational
21.11.2018
Haematologica. A new methodology predicts the risk of relapse in patients with acute myeloid leukemia The acute myeloid leukemia (AML) is the most common haematological cancer in adults. With a 5-year...
David Olmos Translational
13.11.2018
European Urology. First blood-based biomarker in response to the treatment of the most aggressive prostate cancer In collaboration with British and Italian researchers

Up